DeCure for Lacrimal Gland Adenoid Cystic Carcinoma
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Lacrimal Gland Adenoid Cystic Carcinoma — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLacrimal Gland Adenoid Cystic Carcinoma maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lacrimal gland adenoid cystic carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lysine demethylase 6A (KDM6A) — KDM6A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet e7zdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6FUL · 1.649 Å · ligand 1-methyl-5-oxidanyl-4-oxidanylidene-pyridine-2-carboxylic acid (E7Z). Experimental structure, not a prediction.
What the evidence adds up to
In a retrospective series of 20 patients treated between 1952 and 2002 at a single tertiary centre, the median disease-free survival after completion of treatment was 18 months. 16 of 20 patients (80%) developed distant metastasis during follow-up, and 13 patients (65%) died of disease. The median follow-up was 34 months. Seven patients (35%) had local recurrence. Eight patients had a predominantly basaloid histologic pattern, and ten had verifiable perineural invasion. The authors concluded that the prognosis is grave and that no conclusive recommendations for local therapy could be made from the data.
A second series of six patients, reported in 2002, included three men and three women aged 31 to 69 years. Five patients underwent exenteration (alone or extended with radiotherapy), and one had tumour excision followed by radiotherapy. One patient died of carcinoma six years after the first surgery. The median follow-up was 25 months. The authors stated that radical surgery with or without complementary therapy appears to give the best chance of healing in the short or mid term, but the prognosis remains reserved.
A 2021 review of biomarkers in lacrimal gland adenoid cystic carcinoma notes that the tumour is characterised by high recurrence, easy metastasis and poor prognosis. It states that current clinical treatments—surgery, radiotherapy and chemotherapy—still yield a low survival rate. The review calls for further study of the pathogenesis and for identification of biomarkers, but does not report any biomarker that has been validated to change outcomes.
No prospective trial, no randomised comparison of treatment regimens, and no drug therapy with proven efficacy in this disease is described in these abstracts. What is missing is a sufficiently large, prospectively collected cohort or a randomised trial that could test whether any systemic therapy—or any modification of local treatment—improves the consistently poor survival figures. Patient stratification by histologic subtype or perineural invasion status has not been used to guide treatment in a controlled study. Funding for such a trial, and for the collection of tissue for biomarker validation, remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Ophthalmic Plastic and Reconstructive Surgery · 2004 · 156 citations
Outcomes in Patients with Adenoid Cystic Carcinoma of the Lacrimal Gland
AbstractPURPOSE: To evaluate the outcomes among patients with adenoid cystic carcinoma of the lacrimal gland treated at various stages of their disease at a tertiary care cancer center. METHODS: A retrospective case series of 20 patients with adenoid cystic carcinoma of the lacrimal gland treated at a single institution between 1952 and 2002. Clinical records were available for all 20 patients; histologic sections from 12 of the 20 patients were available for review. Disease-free survival was measured from the completion of treatment; overall survival was measured from the date of initial diagnosis. RESULTS: The study included 6 men and 14 women. The mean age at diagnosis was 39.5 years. The median follow-up time was 34 months (range, 6 to 264 months). The local/regional treatment modalities included exenteration with bone removal and radiation therapy (RT) in 5 patients, exenteration with RT (no bone removal) in 8 patients, exenteration (no RT or bone removal) in 1 patient, exenteration with bone removal (no RT) in 1 patient, local resection with RT in 3 patients, and local resection without RT in 2 patients. Overall, 16 patients had RT as part of their treatment regimen. Seven patients (35%) had local recurrence. Sixteen patients (80%) had distant metastasis during the study period. At the time of this report, 13 (65%) of the patients had died of disease. The median disease-free survival for the entire group was 18 months. Eight patients had a predominantly basaloid histologic pattern. Ten patients had verifiable histologic evidence of perineural invasion. CONCLUSIONS: This study underscores the generally grave prognosis for patients with adenoid cystic carcinoma of the lacrimal gland and the difficulty in making any conclusive recommendations for local therapy for this disease.
Klinische Monatsblätter für Augenheilkunde · 2002 · 5 citations
Les adénocarcinomes kystiques de la glande lacrymale
AbstractUNLABELLED: Adenoid cystic carcinoma of the lacrimal gland. BACKGROUND: Adenoid cystic carcinoma is the most frequent epithelial tumour of the lacrimal gland. It represents 1.6 % of the orbital tumours. The aim of this study is to present a series of such patients who were followed up in our clinic and to discuss their clinical management in order to achieve a better life prognosis. MATERIALS AND METHODS: The cases we followed up in our department were presented, the treatment modalities were discussed, and conclusions were drawn. RESULTS: Six patients with this pathology were examined, 3 men and 3 women, aged 31 to 69 years. A large excision was performed in 5 patients (exenteration alone or extended exenteration with complementary radiotherapy) and in 1 patient with excision of the tumour followed by radiotherapy. One patient died due to carcinoma six years after the first surgery. The median follow-up period of our cases is 25 months. CONCLUSION: Adenoid cystic carcinoma of the lacrimal gland is a malignant tumour with a reserved prognosis. Various treatments were proposed to improve the mortality rate of the disease. At present radical surgery with or without complementary therapy seems to give the best chances of healing, at least with short or mid-term follow-up.
DOAJ (DOAJ: Directory of Open Access Journals) · 2021 · 0 citations · open access
Research progress of biomarkers in adenoid cystic carcinoma of lacrimal gland
AbstractAdenoid cystic carcinoma of lacrimal gland(LGACC)is the most common malignant epithelial tumor of the lacrimal gland, which is characterized by high recurrence rate, easy metastasis and poor prognosis. Although the current clinical treatment modalities for adenoid cystic carcinoma of lacrimal gland mainly include surgical resection, radiotherapy, and chemotherapy, its survival rate is still low. Therefore, it is particularly urgent to further study the pathogenesis of adenoid cystic carcinoma of the lacrimal gland and find out the biomarkers for adenoid cystic carcinoma of the lacrimal gland. In this paper, we will review the research progress in biomarkers of adenoid cystic carcinoma of the lacrimal gland.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
